CCDC22

Across TCGA pan-cancer cohorts, CCDC22 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of CCDC22’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where CCDC22 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types CCDC22 is over-expressed in tumor, although a few such as CCRCC and COAD show the opposite, repressed pattern.

CCRCC, COAD, and HNSC are the cancer types where CCDC22 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CCDC22 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	III,IV	−0.353	<.001	11	view →
COAD	Male	II,III,IV	−0.222	<.001	11	view →
HNSC	Male	III,IV	−0.202	<.001	11	view →
LSCC	Male	II,III,IV	−0.489	<.001	9	view →
LUAD	Male	III,IV	−0.366	<.001	9	view →
PDAC	Male	All	+0.328	<.001	6	view →
OV	All	All	−0.332	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

CCDC22–CCRCC

Open the CCRCC breakdown →